Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Bases de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Clin Exp Rheumatol ; 40(7): 1258-1266, 2022 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34251312

RESUMO

OBJECTIVES: To evaluate the incidence of COVID-19 and its main outcomes in rheumatic disease (RD) patients on hydroxychloroquine (HCQ) compared to household cohabitants (HC). METHODS: This is a 24-week nationwide prospective multi-centre cohort with a control group without RD and not using HCQ. All participants were monitored through scheduled phone interviews performed by health professionals. Details regarding COVID-19 symptoms, and epidemiological, clinical, and demographic data were recorded on a specific web-based platform. COVID-19 was defined according to the Brazilian Ministry of Health criteria and classified as mild, moderate or severe. RESULTS: A total of 9,585 participants, 5,164 (53.9%) RD patients on HCQ and 4,421 (46.1%) HC were enrolled from March 29th, 2020 to September 30th, 2020, according to the eligibility criteria. COVID-19 confirmed cases were higher in RD patients than in cohabitants [728 (14.1%) vs. 427 (9.7%), p<0.001] in a 24-week follow-up. However, there was no significant difference regarding outcomes related to moderate/ severe COVID-19 (7.1% and 7.3%, respectively, p=0.896). After multiple adjustments, risk factors associated with hospitalisation were age over 65 (HR=4.5; 95%CI 1.35-15.04, p=0.014) and cardiopathy (HR=2.57; 95%CI 1.12-5.91, p=0.026). The final survival analysis demonstrated the probability of dying in 180 days after a COVID-19 diagnosis was significantly higher in patients over 65 years (HR=20.8; 95%CI 4.5-96.1) and with 2 or more comorbidities (HR=10.8; 95%CI 1.1-107.9 and HR=24.8; 95%CI 2.5-249.3, p=0.006, respectively). CONCLUSIONS: Although RD patients have had a higher COVID-19 incidence than individuals from the same epidemiological background, the COVID-19 severity was related to traditional risk factors, particularly multiple comorbidities and age, and not to underlying RD and HCQ.


Assuntos
Tratamento Farmacológico da COVID-19 , COVID-19 , Doenças Reumáticas , COVID-19/epidemiologia , Teste para COVID-19 , Humanos , Hidroxicloroquina/efeitos adversos , Incidência , Estudos Prospectivos , Doenças Reumáticas/diagnóstico , Doenças Reumáticas/tratamento farmacológico , Doenças Reumáticas/epidemiologia , Fatores de Risco , SARS-CoV-2 , Resultado do Tratamento
2.
Talanta ; 79(4): 1021-5, 2009 Sep 15.
Artigo em Inglês | MEDLINE | ID: mdl-19615502

RESUMO

The present paper describes approaches utilizing the powerful flow manipulation capabilities of sequential injection analysis (SIA) to substantially improve the efficiency of gas-diffusion separation compared to its traditional implementation in flow injection analysis (FIA). Ammonia, ethylamine, diethylamine and triethylamine were used as model analytes in this study. Eleven flow manipulation approaches involving continuous flow, stop-flow, oscillating flow, and the introduction of air bubbles to separate the sample zone from the donor solution were tested. Improvement in sensitivity compared to traditional gas-diffusion FIA exceeding one order of magnitude was achieved. It was observed that this improvement increased with the molecular size of the analyte.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA